{
    "id": 7035,
    "fullName": "MAPK1 P58L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MAPK1 P58L lies within the protein kinase domain of the Mapk1 protein (UniProt.org). P58L results in increased Fos phosphorylation, and has been demonstrated to confer resistance to Raf/Mek inhibitors in culture (PMID: 27760319, PMID: 25320010).",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                },
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5594,
        "geneSymbol": "MAPK1",
        "terms": [
            "MAPK1",
            "ERK",
            "ERK-2",
            "ERK2",
            "ERT1",
            "MAPK2",
            "p38",
            "p40",
            "p41",
            "p41mapk",
            "p42-MAPK",
            "P42MAPK",
            "PRKM1",
            "PRKM2"
        ]
    },
    "variant": "P58L",
    "createDate": "06/04/2015",
    "updateDate": "09/04/2019",
    "referenceTranscriptCoordinates": {
        "id": 145643,
        "transcript": "NM_002745",
        "gDna": "chr22:g.21807793G>A",
        "cDna": "c.173C>T",
        "protein": "p.P58L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2303,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 P58L demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6891,
                "profileName": "MAPK1 P58L"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2302,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 P58L demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6891,
                "profileName": "MAPK1 P58L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14720,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58L in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30283,
                "profileName": "BRAF V600E MAPK1 P58L"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14751,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58L in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30283,
                "profileName": "BRAF V600E MAPK1 P58L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6891,
            "profileName": "MAPK1 P58L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30283,
            "profileName": "BRAF V600E MAPK1 P58L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145644,
            "transcript": "NM_138957",
            "gDna": "chr22:g.21807793G>A",
            "cDna": "c.173C>T",
            "protein": "p.P58L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145643,
            "transcript": "NM_002745",
            "gDna": "chr22:g.21807793G>A",
            "cDna": "c.173C>T",
            "protein": "p.P58L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}